Shares of the American multinational pharmaceutical company Pfizer suffered their biggest monthly decline since 2009 in January.
The decline is due to investors who anticipated a troubled path ahead for the drugmaker’s Covid products.
The stock fell by 15% this month, erasing $43 billion in market value.
In its earnings report on Tuesday, Pfizer presented a weaker-than-estimated sales outlook for its Covid vaccine and pill, and its shares fluctuated.
Pfizer’s shares got a boost throughout the pandemic as its Covid-19 vaccine and pill brought in billions of dollars in sales.
add your comment
Terms of publication : Not to offend the writer, people, sacred things, or attack religions or the divine self, and refrain from racist incitement and insults.